Amicus Therapeutics to Present at Lazard Capital Markets' Healthcare Conference

Amicus Therapeutics to Present at Lazard Capital Markets' Healthcare
Conference

CRANBURY, N.J., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing
therapies for rare and orphan diseases, today announced that William D. Baird,
III, Chief Financial Officer, will present a corporate overview at the Lazard
Capital Markets' 9th Annual Healthcare Conference in New York, NY on
Wednesday, November 14 at 3:30 p.m. ET.

A live webcast of the presentation can be accessed through the Investors
section of the Amicus Therapeutics corporate web site at
http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.
Participants are encouraged to visit the web site 10 minutes prior to the
start of the presentation to register, download and install any necessary
software.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of developing therapies for rare and orphan diseases. The Company is
developing orally-administered, small molecule drugs called pharmacological
chaperones, a novel, first-in-class approach to treating a broad range of
human genetic diseases. Amicus' late-stage programs for lysosomal storage
disorders include migalastat HCl monotherapy in Phase 3 for Fabry disease;
migalastat HCl co-administered with enzyme replacement therapy (ERT) in Phase
2 for Fabry disease; and AT2220 co-administered with ERT in Phase 2 for Pompe
disease.

FOLD–G

CONTACT: Investors/Media:
         Sara Pellegrino
         spellegrino@amicusrx.com
         (609) 662-5044
 
Press spacebar to pause and continue. Press esc to stop.